Know a great AI tool or AI news source? Submit it to AiByts
obesity1 min read

Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

China has approved US pharmaceutical giant Eli Lilly’s weight-loss pill orforglipron, making it the country’s first available oral GLP-1 treatment for obesity as global drug makers seek to tap the country’s massive weight-management market.

By Xinmei ShenSouth China Morning Post Tech
Eli Lilly beats Novo Nordisk to China approval for first oral GLP-1 weight-loss drug

Read the full story

Originally published by South China Morning Post Tech on Nov 13, 2026.

Read on South China Morning Post Tech(opens in a new tab)

Comments

Sign in to join the discussion.

No comments yet — be the first to share your thoughts.